Alpha 2.0
Login Register
» Authors » J Bogaerts

J Bogaerts

Explore the profile of J Bogaerts including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 115
Citations 14694
Followers 0
Related Specialties
Oncology
Infectious Diseases
General Medicine
Top 10 Co-Authors
P van de Perre
H TAELMAN
J Batungwanayo
P Lepage
J Vandepitte
A Kagame
S Allen
J Clerinx
P Kestelyn
P Piot
Published In
Ann Oncol
Ann Soc Belg Med Trop
Eur J Cancer
Lancet
Trans R Soc Trop Med Hyg
Affiliations
Soon will be listed here.
Recent Articles
1.
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
Gyawali B, de Vries E, Dafni U, Amaral T, Barriuso J, Bogaerts J, et al.
ESMO Open . 2021 Apr; 6(3):100117. PMID: 33887690
Background: The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a validated, widely used tool developed to score the clinical benefit from cancer medicines reported in clinical...
2.
Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach
Galot R, Le Tourneau C, Guigay J, Licitra L, Tinhofer I, Kong A, et al.
Ann Oncol . 2018 Oct; 29(12):2313-2327. PMID: 30307465
The molecular landscape of squamous cell carcinoma of the head and the neck (SCCHN) has been characterized and actionable or targetable genomic alterations have been identified. However, targeted therapies have...
3.
Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies
Smoragiewicz M, Bogaerts J, Calvo E, Marabelle A, Perrone A, Seymour L, et al.
Ann Oncol . 2018 Sep; 29(11):2175-2182. PMID: 30202892
The Methodology for the Development of Innovative Cancer Therapies task force considered aspects of the design and conduct of early studies of combinations of immunotherapy agents during their 2018 meeting....
4.
Reply to the letter to the editor 'ESMO-MCBS v1.1: statistical and patient relevant shortcomings' by Emprechtinger et al
Cherny N, Dafni U, Piccart M, Latino N, Douillard J, Bogaerts J, et al.
Ann Oncol . 2018 Apr; 29(5):1335-1338. PMID: 29659680
No abstract available.
5.
Reply to the letter to the editor 'Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies'
Cherny N, Dafni U, Bogaerts J, Latino N, Pentheroudakis G, Douillard J, et al.
Ann Oncol . 2017 Nov; 29(3):774-775. PMID: 29161364
No abstract available.
6.
Reply to the letter to the editor 'Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?' by Del Paggio
Cherny N, Dafni U, Bogaerts J, Latino N, Pentheroudakis G, Douillard J, et al.
Ann Oncol . 2017 Oct; 29(2):521-522. PMID: 29045537
No abstract available.
7.
ESMO-Magnitude of Clinical Benefit Scale version 1.1
Cherny N, Dafni U, Bogaerts J, Latino N, Pentheroudakis G, Douillard J, et al.
Ann Oncol . 2017 Sep; 28(10):2340-2366. PMID: 28945867
Background: The ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) version 1.0 (v1.0) was published in May 2015 and was the first version of a validated and reproducible tool to assess...
8.
Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial
Viale G, de Snoo F, Slaets L, Bogaerts J, van t Veer L, Rutgers E, et al.
Breast Cancer Res Treat . 2017 Sep; 167(1):123-131. PMID: 28929359
Purpose: This study compares immunohistochemical (IHC) versus molecular subtyping (BluePrint and MammaPrint) in the population of patients enrolled in MINDACT and outcome based on molecular subtyping (MS) versus surrogate pathological...
9.
Reply to the letter to the editor 'Addressing the quality of the ESMO-MCBS' by Del Paggio
Cherny N, Dafni U, Bogaerts J, Pentheroudakis G, Tabernero J, Zielinski C, et al.
Ann Oncol . 2017 Apr; 28(8):2031-2032. PMID: 28430861
No abstract available.
10.
Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995...
Tryfonidis K, Marreaud S, Khaled H, de Valk B, Vermorken J, Welnicka-Jaskiewicz M, et al.
Breast Cancer Res Treat . 2017 Mar; 163(3):507-515. PMID: 28324265
Purpose: Cardiotoxicity is a side effect of trastuzumab. We assessed efficacy and cardiac safety of CMF with trastuzumab (CMF+T) in HER2-positive metastatic breast cancer patients (MBC). Methods: In this phase...